Sanara MedTech Inc. (SMTI) Stock Price & Analysis
Sanara MedTech Inc. (SMTI) closed at USD 32.88 on Wednesday, October 28, 2026, up 0.12% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 32.84; the Oct 28, 2026 session ranged USD 32.66–32.98 on volume of 31,948 shares. Market capitalization is $302.10M, with a 52-week range of USD 16.05–35.52 (NCM). Source: Nexqual, retrieved October 29, 2026 at 06:00 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SMTI.md
Key facts (SMTI)
- Last four reported quarters (through Jun 30, 2026): revenue $110M, net income -$32.0M (-29.2% margin), free cash flow $4.5M (SEC filings).
- Analysts: Hold (mean 3.00 on a 1–5 scale) (3 analysts), mean target USD 35 (range 35–35).
- Total return with dividends: 1Y +11.7% vs S&P 500 +13.6%; 5Y -5.8% vs S&P 500 +79.8%.
- Next earnings: 2026-11-11, EPS estimate USD 0.02, revenue estimate $29.5M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SMTI)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $24.1M | $45.8M | $65.0M | $86.7M | $103M | $110M |
| Gross profit | $21.8M | $39.5M | $57.1M | $78.5M | $95.6M | — |
| Operating income | -$7.4M | -$12.5M | -$4.2M | $1.3M | $7.3M | $8.4M |
| Net income | -$7.9M | -$7.9M | -$4.3M | -$9.7M | -$37.6M | -$32.0M |
| EPS (diluted) | -$1.08 | -$1.00 | -$0.52 | -$1.14 | -$4.36 | — |
| Free cash flow | -$5.0M | -$5.7M | -$3.5M | -$230K | $2.2M | $4.5M |
| Gross margin | 90.4% | 86.1% | 87.9% | 90.6% | 92.7% | — |
| Operating margin | -30.6% | -27.3% | -6.5% | 1.5% | 7.1% | 7.7% |
| Net margin | -32.8% | -17.3% | -6.6% | -11.2% | -36.4% | -29.2% |
| Revenue growth | +54.9% | +89.9% | +41.8% | +33.4% | +19.0% | — |
| Cash + short-term investments | $18.7M | $9.0M | $5.1M | $15.9M | $16.6M | — |
| Total debt | — | — | $9.7M | $30.7M | $46.0M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SMTI)
P/S 2.8x · EV/EBITDA 30.6x · EV/Sales 3.0x · P/FCF 67.1x · P/B 38.0x · FCF yield 1.49% · Earnings yield -10.60% · Net debt $31.1M · EV $333M
Analysts (SMTI)
Consensus Hold (mean 3.00 on a 1–5 scale), 3 analysts; mean target USD 35 (low 35, high 35).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-30 | HC Wainwright & Co. | Downgrade | Buy → Neutral | $36 → $35 |
Total return (dividends reinvested) (SMTI)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +11.7% | -5.8% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +11.7% | -1.2% |
| Volatility (annualized) | 58.5% | 49.5% |
| Max drawdown | -44.5% (Oct 2025→Mar 2026) | -65.8% (Apr 2023→Apr 2026) |
SMTI earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.09 | −$0.07 | Beat +$0.16 | — |
| — | Quarter ended Mar 31, 2026 | $0.04 | −$0.22 | Beat +$0.26 | — |
| — | Quarter ended Dec 31, 2025 | −$0.19 | $0.11 | Miss −$0.30 | — |
| — | Quarter ended Sep 30, 2025 | −$3.52 | −$0.21 | Miss −1576.2% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
SMTI recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 28, 2026 | 425 | Merger or acquisition communication |
| Oct 16, 2026 | 425 | Merger or acquisition communication |
| Oct 16, 2026 | 8-K | Other material event “As previously announced, Sanara MedTech Inc., a Texas corporation (the "Company" or "Sanara"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with MiMedx Group, Inc., a Florida corporation ("MiMedx"), and Mustang Merger Sub, Inc., a wholly-owned subsidiary of MiMedx ("Merger Subsidiary"), pursuant to which, among other things and subject to the terms and conditions of the Merger Agreement, Merger Subsidiary will be merged with and into the Company (the "Merger"), with the Company surviving…” |
| Oct 16, 2026 | 425 | Merger or acquisition communication |
| Oct 1, 2026 | 8-K | Shareholder vote results; Other material event “Update on Regulatory Approvals As previously disclosed, MiMedx and Sanara filed their respective notification and report forms pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act") on August 12, 2026. In order to provide the Federal Trade Commission with additional time for review, on September 11, 2026, MiMedx, in consultation with Sanara, voluntarily withdrew its notification and report form pursuant to 16 C.F.R. 803.12 and refiled its notification and report form on…” |
| Aug 20, 2026 | 425 | Merger or acquisition communication |
| Aug 11, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 11, 2026 | 425 | Merger or acquisition communication |
| Aug 11, 2026 | 425 | Merger or acquisition communication |
| Aug 11, 2026 | 8-K | Quarterly results |
| Aug 11, 2026 | 425 | Merger or acquisition communication |
| Aug 11, 2026 | 8-K/A | Entered a material agreement; Regulation FD disclosure “Agreement and Plan of Merger On July 29, 2026, Sanara MedTech Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, MiMedx Group, Inc., a Florida corporation ("Parent") and Mustang Merger Sub, Inc., a Texas corporation and a wholly-owned subsidiary of Parent ("Merger Subsidiary"). Upon the terms and conditions set forth in the Merger Agreement, Merger Subsidiary will be merged with and into the Company (the "Merger"), with the Company surviving the…” |
| Jul 31, 2026 | Schedule 13G/A | Tall Pines Capital, LLC, Stonebridge Wealth Management, LLC: 0.0% of shares, passive 5%+ holder (amended) |
| Jul 30, 2026 | 425 | Merger or acquisition communication |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
SMTI suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Innovations | “January 16, 2025, we entered into a Licensing and Distribution Agreement (as amended, the "BMI License Agreement") with Biomimetic” |
| Related party | Rochal Industries | “July 2021, we entered into an asset purchase agreement with Rochal, a related party.” |
Quoted from the company's 10-K filed Mar 24, 2026.
Companies that name SMTI in their SEC reports
| Relationship to SMTI | Company | Filing | Sentence |
|---|---|---|---|
| partner | InfuSystem Holdings, Inc (INFU) | 10-K Feb 27, 2026 | “In November 2022, the Company established a partnership, SI Healthcare Technologies, LLC ("SI Healthcare"), with Sanara MedTech Inc. ("Sanara").” |
SMTI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.02 | $0.02 | +0.0% | $29.5M | 1 |
| Next quarter (ends Dec 2026) | $0.18 | $0.18 | +0.0% | $31.2M | 1 |
| Current fiscal year (ends Dec 2026) | $0.20 | $0.18 | +11.1% | $116.6M | 1 |
| Next fiscal year (ends Dec 2027) | $0.54 | $0.54 | +0.0% | $133.2M | 1 |
Key Statistics (as of October 29, 2026 at 06:00 UTC)
| Price | USD 32.88 |
|---|---|
| Change | ▲ 0.12% (up) |
| Previous Close | USD 32.84 |
| Open | USD 32.92 |
| Day Range | USD 32.66 – 32.98 |
| 52-Week Range | USD 16.05 – 35.52 |
| Volume | 31,948 shares |
| Market Cap | $302.10M |
| Exchange | NCM |
Technical Analysis (SMTI)
Nexqual's technical model rates SMTI "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 06:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 23.96 (oversold) |
| vs SMA50 | Below (USD 34.56) |
| MACD | -0.5 (negative) |
Analyst Ratings (SMTI)
Wall Street analysts rate SMTI "Hold" based on 3 analysts, with a mean price target of USD 35 (range USD 35–35), per Nexqual as of October 29, 2026 at 06:00 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 35 |
| High Target | USD 35 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 0 / 3 / 0 |
Earnings (SMTI)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD 0.02 |
| Revenue Estimate | $29.50M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.09 vs est -0.07 ▲ beat |
| 2026-03-31 | USD 0.04 vs est -0.22 ▲ beat |
| 2025-12-31 | USD -0.19 vs est 0.11 ▼ miss |
| 2025-09-30 | USD -3.52 vs est -0.22 ▼ miss |
Source: Nexqual, October 29, 2026 at 06:00 UTC.
Financials & Fundamentals (SMTI)
| Total Revenue | $109.81M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +9.00% |
| Gross Margin | +93.03% |
| Operating Margin | +6.33% |
| Profit Margin | -29.15% |
| ROE | -1.32% |
| Debt / Equity | 6.12 |
| Current Ratio | 2.58 |
| Total Cash | $15.42M |
| Total Debt | $48.53M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $4.50M (4.1% of revenue) |
Source: Nexqual, October 29, 2026 at 06:00 UTC.
Financial Health Score (SMTI)
Nexqual rates Sanara MedTech Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 06:00 UTC.
| Growth | Strong — Revenue +19% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 93%, operating 8% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Weak — $15M cash and investments vs $46M debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $5M (last 4 quarters to Jun 2026, SEC), slim 4.1% margin |
| Efficiency | Critical — ROE -403%, ROA -46.3% (last 4 quarters, SEC) |
Ownership (SMTI)
| Insider Ownership | +47.94% |
|---|---|
| Institutional Ownership | +20.39% |
| Shares Outstanding | 9.19M |
| Float | 3.77M |
| Short % of Float | +7.02% |
Source: Nexqual, October 29, 2026 at 06:00 UTC.
Leadership (SMTI)
Sanara MedTech Inc. is led by Seth D. Yon, President, CEO & Director, per Nexqual as of October 29, 2026 at 06:00 UTC.
| President, CEO & Director | Seth D. Yon |
|---|---|
| Executive Chairman | Ronald T. Nixon |
| Chief Financial Officer | Elizabeth B. Taylor |
| Chief Operating Officer | Jacob A. Waldrop |
| Vice President of Marketing | Tricia Matteson |
Major Backers & Investors (SMTI)
Notable institutional backers of Sanara MedTech Inc. include ABC Arbitrage SA, Royal Bank of Canada, AQR Capital Management, LLC, according to Nexqual as of October 29, 2026 at 06:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ABC Arbitrage SA | 2.25% |
| Royal Bank of Canada | 2.09% |
| AQR Capital Management, LLC | 1.79% |
| Fidelity | 1.58% |
| Goldman Sachs | 1.18% |
| Renaissance Technologies | 1.08% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 3.97% |
| Vanguard Group | 3.11% |
| Geode Capital | 1.42% |
| State Street | 1.01% |
Source: Nexqual, October 29, 2026 at 06:00 UTC.
From Sanara MedTech Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- With the aim of optimizing commercial and regulatory success, our proprietary technology and innovative applications thereof are protected by product, system, process and method-of-use patent claims.
- The FDA regulates the development, testing, manufacturing, labeling, packaging, storage, installation, servicing, advertising, promotion, marketing, distribution, import, export and market surveillance of our medical devices. addition, we market certain products for use in surgical wound care regulated by the FDA under Section 361 of the Public Health Service Act ("PHSA") (42 U.S.C. § 264) and 21 C.F.R.
- Class I devices are those for which reasonable assurance of safety and effectiveness can be assured by adherence to general controls that include compliance with the applicable portions of the FDA's Quality Management System Regulation ("QMSR"), as well as regulations requiring facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising and promotional materials.
- We believe the breadth and flexibility of the products we offer allow us to address a wide variety of surgical site needs, wound types and sizes and offer significant new opportunities for sales growth.
Partnerships
- December 20, 2023, we signed an exclusive license agreement with Tufts University ("Tufts") to develop and commercialize patented technology covering 18 unique collagen peptides.
- By mid-September 2025, we concluded that these efforts were unlikely to succeed within the timeline allocated by the Board of Directors and ended our engagement with the investment bank.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AZTA | Azenta, Inc. | USD 40.63 | ▲ 3.97% |
| XRAY | DENTSPLY SIRONA Inc. | USD 9.44 | ▲ 0.96% |
| LMAT | LeMaitre Vascular, Inc. | USD 82.87 | ▼ 1.1% |
| WRBY | Warby Parker Inc. | USD 24.43 | ▼ 2.55% |
| ATRC | AtriCure, Inc. | USD 61.42 | ▼ 0.15% |
| PLSE | Pulse Biosciences, Inc | USD 53.67 | ▲ 0.88% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:00 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt